
At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
In an era defined by uncertainty and increasing organizational complexity, the pressure on health and life science leaders to drive successful launches has reached a critical point. Traditional playbooks for bringing assets to market are being rewritten by technological shifts, shorter clinical-to-launch timelines, and a competitive landscape that moves faster than ever before. To explore what separates high-performing organizations from the rest, Remco op den Kelder, Global President of Inizio Ignite dives into leadership strategies that will define the next three to five years of the industry.
Key Objectives






